Vicriviroc in Treatment-Naive Patients

In a phase II study, higher rates of virologic failure were seen with regimens containing low doses of vicriviroc than with regimens containing efavirenz.

Vicriviroc is an investigational CCR5 inhibitor that seemed promising in industry-funded, phase I clinical trials involving treatment-naive HIV-infected patients. However, recent results from a phase II trial of this drug (also industry funded) are less encouraging.

A total of 92 treatment-naive patients with CCR5-tropic virus only were randomized to receive double-blinded, once-daily vicriviroc (25 mg, 50 mg, or 75 mg) or placebo for 14 days, followed by combination therapy with either vicriviroc or open-label efavirenz, each with AZT/3TC, for 48 weeks.

Results looked promising at day 14 of monotherapy, with significantly greater mean decreases in viral load in the three vicriviroc groups than in the placebo group. However, 4 weeks into the …

Reviewing Author

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Vicriviroc in Treatment-Naive Patients

Topics

Reviewing Author